Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on NBIX stock, giving a Buy rating on April 2.
Tazeen Ahmad has given his Buy rating due to a combination of factors that highlight Neurocrine’s strong market position and growth potential. The company’s CEO, Kyle Gano, expressed confidence in managing the impact of global tariffs, thanks to high product margins that provide a buffer against increased costs. Additionally, recent FDA restructuring changes are not expected to affect the company’s pipeline timelines, as there are no major regulatory interactions pending.
Furthermore, despite anticipated commercial headwinds affecting Ingrezza sales in the first quarter, Gano remains optimistic about a sales recovery in the second quarter and a reacceleration in the second half of the year. This optimism is supported by the expansion of the salesforce and ongoing payor contracting efforts. The upcoming launch of Crenessity is also expected to contribute to growth, with increasing demand anticipated as awareness of the drug grows. These factors, combined with a strong established franchise, underpin the Buy rating with a price objective of $179.
Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Vertex Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Ahmad has an average return of -4.6% and a 43.21% success rate on recommended stocks.
In another report released on April 2, Wells Fargo also maintained a Buy rating on the stock with a $180.00 price target.